Shopping Cart 0
Cart Subtotal
USD 0

Intra-Cellular Therapies Inc (ITCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company's lead product candidate ITI-007-lumateperone is to treat schizophrenia, behavioural disturbances in dementia, sleep and behavioural disturbances associated with autism spectrum disorder, other mood disorders, sleep disturbances associated with neurologic and psychiatric disorders, and others. Its CNSProfile technology monitors the phosphoprotein changes and generates a unique molecular signature for drug compounds. The company utilizes phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. ITI is headquartered in New York, the US.

Intra-Cellular Therapies Inc (ITCI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Intra-Cellular Therapies Raises USD 15 Million In Venture Financing 10

Merger 11

Intra-Cellular Therapies And Public Shell Company Complete Reverse Merger Transaction 11

Licensing Agreements 12

Intra-Cellular Therapies Enters Into Licensing Agreement with ITI 12

Equity Offering 13

Intra-Cellular Therapies Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD172 Million 13

Intra-Cellular Therapies Raises USD345.2 Million in Public Offering of Shares 15

Intra-Cellular Therapies Raises USD130 Million in Public Offering of Shares 17

Intra-Cellular Therapies Completes Public Offering Of Shares For USD 123.6 Million 19

Intra-Cellular Therapies Completes Private Placement Of Shares For USD 44.7 Million 21

Intra-Cellular Therapies Inc-Key Competitors 23

Intra-Cellular Therapies Inc-Key Employees 24

Intra-Cellular Therapies Inc-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

Aug 02, 2018: Intra-Cellular Therapies provides corporate update and reports second quarter 2018 financial results 26

May 03, 2018: Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update 28

Mar 01, 2018: Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 30

Nov 08, 2017: Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33

Aug 09, 2017: Intra-Cellular Therapies Reports Second Quarter 2017 Financial Results and Provides Corporate Update 35

May 10, 2017: Intra-Cellular Therapies Reports First Quarter 2017 Financial Results and Provides Corporate Update 37

Mar 01, 2017: Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 39

Corporate Communications 41

Oct 16, 2018: Intra-Cellular Therapies appoints Mark Neumann as executive vice president, chief commercial officer 41

Sep 25, 2018: Intra-Cellular Therapies names Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs 42

Nov 13, 2017: Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intra-Cellular Therapies Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Intra-Cellular Therapies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Intra-Cellular Therapies Raises USD 15 Million In Venture Financing 10

Intra-Cellular Therapies And Public Shell Company Complete Reverse Merger Transaction 11

Intra-Cellular Therapies Enters Into Licensing Agreement with ITI 12

Intra-Cellular Therapies Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD172 Million 13

Intra-Cellular Therapies Raises USD345.2 Million in Public Offering of Shares 15

Intra-Cellular Therapies Raises USD130 Million in Public Offering of Shares 17

Intra-Cellular Therapies Completes Public Offering Of Shares For USD 123.6 Million 19

Intra-Cellular Therapies Completes Private Placement Of Shares For USD 44.7 Million 21

Intra-Cellular Therapies Inc, Key Competitors 23

Intra-Cellular Therapies Inc, Key Employees 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Intra-Cellular Therapies Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.